WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Credit Suisse 30th Annual Healthcare Conference and participate in fireside chats at the Jefferies London Healthcare Conference and the Evercore ISI 4th Annual HealthCONx Conference. Credit Suisse 30th Annual Healthcare ConferenceFormat:Corporate PresentationDate:Monday, November 8, 2021Time:8:50am EST Jefferies London Healthcare ConferenceFormat:Fireside ChatDate:Thursday, November 18, 2021Time:8:00am GMTWebcast Link Evercore ISI 4th Annual HealthCONx ConferenceFormat:Fireside ChatDate:Wednesday, December 1, 2021Time:10:55am ESTWebcast Link About Viridian Therapeutics Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). TED is a debilitating auto immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts. Viridian Contacts:Investors:Dan FerryLifeSci Advisors617-430-7576IR@viridiantherapeutics.com Media:Darby PearsonVerge Scientific Communications703-587-0831PR@viridiantherapeutics.com